Seven drugs slated for approval in 2025 could revolutionize treatment for various rare diseases. These include diazoxide choline for Prader-Willi syndrome, fitusiran for hemophilia, elamipretide for Barth syndrome, nipocalimab for myasthenia gravis, plozasiran for familial chylomicronemia syndrome, sebetralstat for hereditary angioedema, and taletrectinib for ROS1-positive non-small cell lung cancer. These drugs aim to improve the lives of those with rare conditions, demonstrating recent advancements in research, diagnosis, and treatment.
Healthcare Security is Homeland Security: A Discussion with Jonathan Meyer | Sheppard Mullin Richter & Hampton LLP
Healthcare has become a major target for cyber threats, with potential to compromise national security. In light of this, Jonathan Meyer, ex-General Counsel of Homeland
